Xilio Therapeutics, Inc. Deferred Revenue Recognized
Xilio Therapeutics, Inc. (XLO) reported Deferred Revenue Recognized of $31.34 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2026-08-12
- Xilio Therapeutics, Inc. contract with customer, liability, revenue recognized for the quarter ending 2026-03-31 was $12.65M, a 331.67% increase year-over-year.
- Xilio Therapeutics, Inc. contract with customer, liability, revenue recognized for the quarter ending 2025-03-31 was $2.93M.
- Xilio Therapeutics, Inc. contract with customer, liability, revenue recognized for fiscal 2025 was $43.77M.
| Period end | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 6 month | Contract with Customer, Liability, Revenue Recognized 9 month | Contract with Customer, Liability, Revenue Recognized 12 month |
|---|---|---|---|---|
| 2026-06-30 | $31.34M 10-Q · filed 2026-08-12 | |||
| 2026-03-31 | $12.65M 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | $43.77M 10-K · filed 2026-03-23 | |||
| 2025-09-30 | $30.08M 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | $11.01M 10-Q · filed 2025-08-14 | |||
| 2025-03-31 | $2.93M 10-Q · filed 2025-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 |